These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 32880356)

  • 1. What Clinicians and Health Professions Students Should Learn About How Pharmaceutical Marketing Influences Opioid Prescribing and Patient Outcomes.
    Erdek MA
    AMA J Ethics; 2020 Aug; 22(1):E681-686. PubMed ID: 32880356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical opioid marketing and physician prescribing behavior.
    Beilfuss S; Linde S
    Health Econ; 2021 Dec; 30(12):3159-3185. PubMed ID: 34562329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of pharmaceutical marketing mix strategies on physicians' prescribing behaviors in public and private hospitals, Dessie, Ethiopia: a mixed study design.
    Hailu AD; Workneh BD; Kahissay MH
    BMC Public Health; 2021 Jan; 21(1):65. PubMed ID: 33413248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Pharmaceutical Industry Marketing of Opioid Products to Physicians With Subsequent Opioid Prescribing.
    Hadland SE; Cerdá M; Li Y; Krieger MS; Marshall BDL
    JAMA Intern Med; 2018 Jun; 178(6):861-863. PubMed ID: 29799955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical marketing strategies' influence on physicians' prescribing pattern in Lebanon: ethics, gifts, and samples.
    Khazzaka M
    BMC Health Serv Res; 2019 Jan; 19(1):80. PubMed ID: 30700295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact Of Academic Medical Center Policies Restricting Direct-To-Physician Marketing On Opioid Prescribing.
    Eisenberg MD; Stone EM; Pittell H; McGinty EE
    Health Aff (Millwood); 2020 Jun; 39(6):1002-1010. PubMed ID: 32479218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Pharmaceutical Industry Marketing of Opioid Products With Mortality From Opioid-Related Overdoses.
    Hadland SE; Rivera-Aguirre A; Marshall BDL; Cerdá M
    JAMA Netw Open; 2019 Jan; 2(1):e186007. PubMed ID: 30657529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced Opioid Marketing Could Limit Prescribing Information for Physicians.
    Ippolito B; Veuger S
    JAMA Intern Med; 2018 Oct; 178(10):1427. PubMed ID: 30285131
    [No Abstract]   [Full Text] [Related]  

  • 9. Reduced Opioid Marketing Could Limit Prescribing Information for Physicians-Reply.
    Hadland SE; Cerdá M; Marshall BDL
    JAMA Intern Med; 2018 Oct; 178(10):1426-1427. PubMed ID: 30285139
    [No Abstract]   [Full Text] [Related]  

  • 10. Student understanding of the relationship between the health professions and the pharmaceutical industry.
    Monaghan MS; Galt KA; Turner PD; Houghton BL; Rich EC; Markert RJ; Bergman-Evans B
    Teach Learn Med; 2003; 15(1):14-20. PubMed ID: 12632703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of pharmaceutical companies' marketing mix strategies on physicians prescribing practices in Jordan: a cross-sectional study.
    Al Thabbah DH; Almahairah MS; Naser AY; Alrawashdeh HM; Araidah M
    BMC Health Serv Res; 2022 Oct; 22(1):1293. PubMed ID: 36303214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of marketing in pharmaceutical research and development.
    Calfee JE
    Pharmacoeconomics; 2002; 20 Suppl 3():77-85. PubMed ID: 12457428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid pharmacovigilance: A clinical-social history of the changes in opioid prescribing for patients with co-occurring chronic non-cancer pain and substance use.
    Knight KR; Kushel M; Chang JS; Zamora K; Ceasar R; Hurstak E; Miaskowski C
    Soc Sci Med; 2017 Aug; 186():87-95. PubMed ID: 28599142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reconciling a "pleasant exchange" with evidence of information bias: A three-country study on pharmaceutical sales visits in primary care.
    Reynolds E; Guénette L; Lexchin J; Cassels A; Wilkes MS; Durrieu G; Beaulieu MD; Mintzes B
    Health Policy; 2018 Mar; 122(3):250-255. PubMed ID: 29395543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in opioid marketing practices after release of the CDC guidelines.
    Togun AT; Karaca-Mandic P; Wurtz R; Jeffery MM; Beebe T
    Am J Manag Care; 2022 Oct; 28(10):507-513. PubMed ID: 36252169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical marketing research and the prescribing physician.
    Greene JA
    Ann Intern Med; 2007 May; 146(10):742-8. PubMed ID: 17502635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical payments to physicians may increase prescribing for opioids.
    Nguyen TD; Bradford WD; Simon KI
    Addiction; 2019 Jun; 114(6):1051-1059. PubMed ID: 30667135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health Care Clinicians and Product Promotion by Industry.
    Diekema DS;
    Pediatrics; 2022 Apr; 149(4):. PubMed ID: 35977093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid Prescribing and the Ethical Duty to
    Nicholson KM; Hellman D
    Am J Law Med; 2020 May; 46(2-3):297-310. PubMed ID: 32659195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gifts and influence: Conflict of interest policies and prescribing of psychotropic medications in the United States.
    King M; Bearman PS
    Soc Sci Med; 2017 Jan; 172():153-162. PubMed ID: 27856120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.